Moderna (NASDAQ: MRNA) delivered a Q2 better than feared, not good in absolute terms. Revenue of $145 million beat the $103 million consensus by 41%. GAAP EPS of $(1.97) edged past the $(2.03) estimate. But the headline beat masks a business still in transition. COVID vaccine sales keep falling in the U.S. and South America, offset this quarter by deliveries under a long-term UK government partnership and higher stand-ready manufacturing and collaboration revenue. The $94 million in net product sales was actually down 18% from $114 million a year ago. The beat came entirely from the $51 million in other revenue, which nearly doubled from $28 million in Q2 2025.
The real story this quarter is cost discipline. Moderna lowered its full-year 2026 GAAP operating expense outlook by approximately $0.2 billion. R&D is now guided to $2.9 billion, down from $3.0 billion. Cost of sales is guided to $1.7 billion, down from $1.8 billion. That $0.2 billion reduction flows directly to the year-end cash projection, raised to $4.7–5.2 billion from the prior range. The company ended Q2 with $6.9 billion in cash and investments, then paid $950 million in July for the litigation settlement announced in Q1. Excluding that one-time outflow, the cash trajectory would look even stronger. Management is signaling that restructuring and pipeline prioritization are yielding measurable results. The reiterated revenue growth target of up to 10% for 2026 implies confidence that second-half deliveries—weighted 55% to Q3—will materialize.
But the pipeline narrative took a hit. The norovirus vaccine candidate mRNA-1403 failed to meet statistical criteria for early success at the Phase 3 interim analysis. The trial continues blinded, and Moderna will enroll an additional cohort. This is a setback for a program that was one of the more visible near-term catalysts outside of flu and COVID. Norovirus represents a large unmet need, yet the delay and additional enrollment push the readout further out and add cost. The company did not disclose the magnitude of the miss or the new timeline, leaving investors to guess at the probability of eventual success.
The offset is the potential approval of mFLUSIVA, Moderna's seasonal flu vaccine, with an August 5 PDUFA date. Approval would make it the company's fifth marketed product and open a new revenue stream beyond COVID. The VRBPAC unanimous recommendation in June was a strong signal, but the market has already partially priced in approval. Real upside would come from commercial uptake and whether mFLUSIVA can carve share from Sanofi and CSL Seqirus in a crowded flu market.
On the oncology front, the intismeran (mRNA-4157) program with Merck remains the most valuable pipeline asset. Five-year Phase 2b adjuvant melanoma data showed a 49% reduction in risk of recurrence or death versus KEYTRUDA alone. This durable benefit supports the ongoing Phase 3 adjuvant melanoma study, with data potentially in 2026. A positive readout would validate the mRNA platform beyond infectious disease and could unlock a multi-billion-dollar opportunity. But it is binary and still months away.
The cost cuts are welcome. They are not a growth strategy. Moderna is tightening its belt while waiting for new products to scale. The Q2 beat was driven by lumpy collaboration and government revenue, not sustainable commercial momentum. The norovirus miss is a reminder that pipeline execution remains uncertain. For the stock to re-rate meaningfully, the market needs to see either accelerating product revenue from mFLUSIVA and mRESVIA or a positive Phase 3 readout for intismeran. Until then, this is a story of financial prudence masking operational transition.